This research project will be based on Cellworks proprietary iC-PHYS Tumor Cell platform, which is Multi Drug Resistance (MDR) Aware technology and enables virtual prototyping to incorporate drug-resistance factors in the drug discovery process. Also the various cancer phenotypes are comprehensively included in this technology platform.
"Transparency into all cancer phenotypes and intermediate nodes simultaneously through the iC-PHYS platform and correlation with the clinical data points will expand opportunities for personalised medicine in cancer treatment," said Taher Abbasi, chief executive officer, Cellworks.
According to Dr J S RajKumar, founder and chairman, Lifeline Hospitals, "We are partnering with Cellworks Group Inc. to better understand the details of the cellular bio-chemical pathways and proteins involved in the differentiation process. Cellworks team with its in-depth expertise in cellular modelling and rich library of in silico based proprietary platforms has been identified to be the optimal partner in this exciting and emergent area." |
